EDINBURGH, Scotland, Aug. 15,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
the closing of its previously announced public offering of
2,000,000 shares of its American Depository Shares ("ADSs")(or
pre-funded warrants in lieu thereof), together with Series G
warrants ("Series G Warrants") to purchase up to 2,000,000 ADSs at
a combined public offering price of $1 per ADS (or
pre-funded warrant in lieu thereof) and associated Series G
Warrant. The Series G Warrants have an exercise price of
£0.78 per ADS, are exercisable upon issuance and will expire
one year from the date of issuance. Each ADS represents two
hundred ordinary shares of the Company.
The gross proceeds to the Company from the
offering were $2.0 million, before
deducting offering expenses payable by the Company. The
Company intends to use the net proceeds from this offering to
support its upcoming clinical trial focusing on relapse/refractory
Acute Myeloid Leukemia, and for continuing operating expenses and
working capital.
A registration statement on Form F-1 (File No. 333-280659)
relating to these securities described above was filed with the
Securities and Exchange Commission, or the SEC, and was declared
effective by the SEC on August 12,
2024. The offering was made only by means of a prospectus,
which is part of the effective registration statement. A final
prospectus relating to the offering was filed with the SEC.
Electronic copies of the final prospectus may be obtained for free
on the SEC's website located at http://www.sec.gov.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
other jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this press release.
The Company undertakes no obligation to update forward-looking
statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-closing-of-2-0-million-public-offering-302223649.html
SOURCE TC BioPharm